サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1206305

欧州のインフルエンザワクチンの2028年までの市場予測-地域分析-ワクチンタイプ、ウイルスタイプ、技術、投与経路、ターゲットグループ別

Europe Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group
出版日: | 発行: The Insight Partners | ページ情報: 英文 156 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
欧州のインフルエンザワクチンの2028年までの市場予測-地域分析-ワクチンタイプ、ウイルスタイプ、技術、投与経路、ターゲットグループ別
出版日: 2023年01月11日
発行: The Insight Partners
ページ情報: 英文 156 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州のインフルエンザワクチン市場は、2022年の22億6,185万米ドルから2028年には34億2,402万米ドルに成長すると予測、2022年から2028年までのCAGRは7.2%と推定されています。

トップ企業と政府による投資の増加が欧州インフルエンザワクチン市場を押し上げる

世界中の市場プレイヤーや政府は、ワクチン開発や予防接種への投資を増やしています。例えば、2021年3月、サノフィ（フランス・パリ）は、カナダ・トロントの既存施設にある新しいワクチン製造工場に約9億2,500万米ドルを投資すると発表しました。新施設への投資により、サノフィの高用量4価インフルエンザワクチン「FLUZONE」の抗原および充填能力が追加され、今後数年間、カナダ、米国、欧州での入手性が高まります。2021年4月、連邦、州、市の3つのレベルの政府が、サノフィパスツールのトロントでの「エンドツーエンド」インフルエンザワクチン工場建設を支援しました。パートナーは10億米ドルを投資し、2027年までにこの施設を稼働させる予定です。サノフィは、5,500万米ドル以上を投資し、165の新規雇用を創出し、さらに1100の雇用を維持する予定です。さらに、サノフィはカナダでの研究開発資金として、8年間にわたり毎年7,900万米ドルを投資します。

2021年6月、欧州投資銀行は、バイオテクノロジー企業のユニヴェルセルズと、ベルギーの新拠点でCOVID-19ワクチンを大量生産するための3,055万米ドルの世界ワクチン販売契約を締結しました。その他、世界各地でのワクチン工場の建設を支援しました。2022年4月には、イタリアの生物医学研究企業であるIRBMに対し、ワクチン生産能力の拡大とCOVID-19などの研究強化のため、1,527万米ドルの融資を実施しました。このように、地域のトップ市場企業や政府による投資の増加が、欧州インフルエンザワクチン市場を後押ししています。

市場概要

欧州は、高齢者人口の増加、インフルエンザや関連疾患の流行、新しいワクチンの開発需要の高まりなどの要因により、第2位の市場規模を占めています。また、研究開発への資金援助が増加していることから、同地域では今後数年間、より多くのビジネスチャンスがもたらされるものと思われます。

欧州インフルエンザワクチン市場の収益と2028年までの予測（百万米ドル）

欧州のインフルエンザワクチン市場のセグメンテーション

欧州インフルエンザワクチン市場は、ワクチンタイプ、ウイルスタイプ、技術、投与経路、ターゲットグループ、国に基づいてセグメント化されています。

ワクチンタイプに基づき、欧州インフルエンザワクチン市場は4価ワクチンと3価ワクチンに二分化されます。4価ワクチンセグメントは、2022年に市場でより大きなシェアを登録しました。

ウイルスタイプに基づき、欧州インフルエンザワクチン市場はインフルエンザウイルスA型とインフルエンザウイルスB型に二分され、2022年にはインフルエンザウイルスA型セグメントが市場でより大きなシェアを占めました。

技術に基づき、欧州インフルエンザワクチン市場は、卵ベースと細胞ベースに分けられます。2022年の市場では、卵ベースのセグメントがより大きなシェアを占めています。

投与経路に基づき、欧州インフルエンザワクチン市場は、注射と鼻腔スプレーに分けられます。2022年の市場では、注射剤がより大きなシェアを占めています。

ターゲットグループに基づき、欧州インフルエンザワクチン市場は、乳幼児、小児、成人、高齢者に区分けされます。2022年の市場では、乳幼児セグメントが最も大きなシェアを占めています。

国別では、欧州インフルエンザワクチン市場は、英国、ドイツ、フランス、イタリア、スペイン、その他欧州に区分されます。2022年には英国が市場を独占しました。

AstraZeneca;Emergent BioSolutions Inc.;GlaxoSmithKline plc.;Mitsubishi Chemical Group Corporation;Moderna, Inc.;MYLAN N.V.;Sanofi;SEQIRUS;Serum Institute of India Pvt. Ltdは、欧州のインフルエンザワクチン市場で活動している主要企業です。

目次

第1章 イントロダクション

  • 調査範囲
  • 洞察パートナーズの調査報告書ガイダンス
  • 市場セグメンテーション
    • 欧州のインフルエンザワクチン市場：ワクチンタイプ別
    • 欧州のインフルエンザワクチン市場：ウイルスタイプ別
    • 欧州のインフルエンザワクチン市場：技術別
    • 欧州インフルエンザワクチン市場：投与経路別
    • 欧州インフルエンザワクチン市場：ターゲットグループ別
    • 欧州のインフルエンザワクチン市場：国別

第2章 欧州のインフルエンザワクチン市場：主要なポイント

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 欧州のインフルエンザワクチン市場-市場情勢

  • PEST分析
    • 欧州のPEST分析
  • 専門家別オピニオン

第5章 欧州のインフルエンザワクチン市場-主要な市場力学

  • 市場促進要因
    • インフルエンザワクチン接種を促進するための政府支援の増加
    • トップ企業と政府別投資の増加
  • 市場抑制要因
    • ワクチン開発コストの高さ
  • 市場機会
    • 新興国
  • 今後の動向
    • インフルエンザワクチンの強力な候補パイプライン
  • インパクトのある分析

第6章 インフルエンザワクチン市場-欧州の分析

  • 欧州のインフルエンザワクチン市場：国別予測・分析
  • 欧州のインフルエンザワクチン市場の収益予測と分析
    • 欧州：インフルエンザワクチン市場、2019年～2028年

第7章 欧州のインフルエンザワクチン市場の分析と2028年までの予測-ワクチンタイプ別

  • 欧州のインフルエンザワクチン市場、ワクチンタイプ別2022年・2028年（%）
  • 4価ワクチン
  • 3価ワクチン

第8章 欧州インフルエンザワクチン市場の分析と2028年までの予測：ウイルスタイプ別

  • 欧州インフルエンザワクチン市場：ウイルスタイプ別2022年・2028年（%）
  • インフルエンザウイルスA型
  • インフルエンザウイルスB型

第9章 欧州のインフルエンザワクチン市場の分析と2028年までの予測：技術別

  • 欧州のインフルエンザワクチン市場：技術別2022年・2028年（%）
  • 卵子ベース
  • 細胞ベース

第10章 欧州インフルエンザワクチン市場の分析と2028年までの予測：投与経路別

  • 欧州のインフルエンザワクチン市場：投与経路別2022年・2028年（%）
  • 注射剤
  • 鼻腔スプレー

第11章 欧州インフルエンザワクチン市場の分析と2028年までの予測：ターゲットグループ別

  • 欧州インフルエンザワクチン市場：ターゲットグループ別2022年・2028年（%）
  • 乳幼児
  • 小児
  • 成人
  • 高齢者（Elderly People

第12章 欧州インフルエンザワクチン市場の分析と2028年までの予測：国別分析

  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州

第13章 欧州のインフルエンザワクチン市場-業界情勢

  • インフルエンザワクチン市場の成長戦略、2021年～2028年
  • 無機的な成長戦略
  • 有機的成長戦略

第14章 企業プロファイル

  • Moderna, Inc.
  • SEQIRUS
  • Sanofi
  • GlaxoSmithKline plc.
  • Emergent BioSolutions Inc.
  • Mitsubishi Chemical Group Corporation
  • Serum Institute of India Pvt. Ltd
  • MYLAN N.V.
  • AstraZeneca

第15章 付録

  • The Insight Partners について
  • 用語集
図表

List Of Tables

  • Table 1. Below are a few instances of companies and their pipeline products:
  • Table 2. Europe Influenza Vaccines Market- Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Europe Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Europe: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. Europe Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. Europe Influenza Vaccines Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Europe Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 8. Germany Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. Germany: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. Germany Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Germany Influenza Vaccines Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Germany Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 13. UK Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. UK: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. UK Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. UK Influenza Vaccines Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 17. UK Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 18. France Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. France: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. France Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. France Influenza Vaccines Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. France Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 23. Italy Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Italy: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Italy Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Italy Influenza Vaccines Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Italy Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 28. Spain Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Spain: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Spain Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Spain Influenza Vaccines Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Spain Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 33. Rest of Europe Influenza Vaccines Market, by Vaccine Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 34. Rest of Europe: Influenza Vaccines Market, by Virus Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 35. Rest of Europe Influenza Vaccines Market, by Technology - Revenue and Forecast to 2028 (US$ Million)
  • Table 36. Rest of Europe Influenza Vaccines Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
  • Table 37. Rest of Europe Influenza Vaccines Market, by Target Group- Revenue and Forecast to 2028 (USD Million)
  • Table 38. Recent Inorganic Growth Strategies in the Influenza Vaccine Market
  • Table 39. Recent Organic Growth Strategies in the Influenza Vaccine Market
  • Table 40. Glossary of Terms, Influenza Vaccines Market

List Of Figures

  • Figure 1. Europe Influenza Vaccines Market Segmentation
  • Figure 2. Europe Influenza Vaccines Market Segmentation, by Country
  • Figure 3. Europe Influenza Vaccines Market Overview
  • Figure 4. Quadrivalent Vaccines Segment Held Largest Share of Product Segment in Europe Influenza Vaccines Market
  • Figure 5. UK Is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 6. Europe: PEST Analysis
  • Figure 7. Experts Opinion
  • Figure 8. Europe Influenza Vaccines Market - Revenue Forecasts and Analysis - 2020- 2028
  • Figure 9. Europe Influenza Vaccines Market, by Vaccine Type 2022 & 2028 (%)
  • Figure 10. Quadrivalent Vaccines: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 11. Trivalent Vaccines: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 12. Europe Influenza Vaccines Market, by Virus Type 2022 & 2028 (%)
  • Figure 13. Influenza Virus Type A : Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 14. Influenza Virus Type B: Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 15. Europe Influenza Vaccines Market, by Technology 2022 & 2028 (%)
  • Figure 16. Egg-based: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 17. Cell-Based: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 18. Europe Influenza Vaccines Market, by Route of Administration 2022 & 2028 (%)
  • Figure 19. Injection: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 20. Nasal Spray: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 21. Europe Influenza Vaccines Market, by Target Group 2022 & 2028 (%)
  • Figure 22. Infants : Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 23. Children: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 24. Adults: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 25. Elderly People: Europe Influenza Vaccines Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 26. Europe: Influenza Vaccines Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 27. Europe: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
  • Figure 28. Germany: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. UK: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. France: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. Italy: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Spain: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Rest of Europe: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Growth Strategies in the Influenza Vaccine Market, 2021-2028
目次
Product Code: BMIRE00026929

The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028; it is estimated to grow at a CAGR of 7.2% from 2022 to 2028.

Increasing Investment by Top Market Players and Governments Boosts Europe Influenza Vaccines Market

Market players and governments worldwide are increasing their investments in vaccine development and immunization. For instance, in March 2021, Sanofi (Paris, France) announced an approximately US$ 925 million investment in a new vaccine manufacturing plant at its pre-existing site in Toronto, Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US, and Europe in the coming years. In April 2021, 3 levels of government-federal, provincial, and municipal-supported Sanofi Pasteur in building an "end-to-end" influenza vaccines factory in Toronto. The partners will invest ~US$ 1 billion to get the site up and running by 2027. Sanofi, for its part, will invest more than US$ 55 million, create 165 new eligible jobs, and maintain another 1,100. In addition, Sanofi will also invest ~US$ 79 million annually for 8 years to fund research and development in Canada.

In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories across the world. In April 2022, the bank provided a US$ 15.27 million loan to IRBM, an Italian biomedical research company, to expand its vaccine production capacity and strengthen research on COVID-19 and other diseases. Thus, the increase in investment by top market players and governments across the region is bolstering the Europe influenza vaccines market.

Market Overview

Europe accounted for the second largest market owing to factors such as the rising geriatric population, increasing prevalence of flu and related illness, and growing demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to provide more opportunities in the coming years across the region.

Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Europe Influenza Vaccines Market Segmentation

The Europe influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the Europe influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Europe influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Europe influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Europe influenza vaccines market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Influenza Vaccines Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution

Table Of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Influenza Vaccines Market - By Vaccine Type
    • 1.3.2 Europe Influenza Vaccines Market - By Virus Type
    • 1.3.3 Europe Influenza Vaccines Market - By Technology
    • 1.3.4 Europe Influenza Vaccines Market - By Route of Administration
    • 1.3.5 Europe Influenza Vaccines Market - By Target Group
    • 1.3.6 Europe Influenza Vaccines Market - By Country

2. Europe Influenza Vaccines Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Influenza Vaccines Market - Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Europe PEST Analysis
  • 4.3 Experts Opinion

5. Europe Influenza Vaccines Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Government Support to Promote Influenza Vaccination
    • 5.1.2 Increasing Investment by Top Market Players and Governments
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Vaccine Development
  • 5.3 Market Opportunities
    • 5.3.1 Emerging Economies
  • 5.4 Future Trends
    • 5.4.1 Strong Pipeline Candidates for Influenza Vaccines
  • 5.5 Impact Analysis

6. Influenza Vaccine Market -Europe Analysis

  • 6.1 Europe Influenza Vaccines Market, By Country - Forecasts And Analysis
  • 6.2 Europe Influenza Vaccines Market Revenue Forecasts And Analysis
    • 6.2.1 Europe: Influenza Vaccines Market, 2019-2028 (US$ Million)

7. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Vaccine Type

  • 7.1 Overview
  • 7.2 Europe Influenza Vaccines Market, By Vaccine Type 2022 & 2028 (%)
    • 7.2.1 Europe: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
  • 7.3 Quadrivalent Vaccines
    • 7.3.1 Overview
    • 7.3.2 Quadrivalent Vaccines : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 7.4 Trivalent Vaccines
    • 7.4.1 Overview
    • 7.4.2 Trivalent Vaccines : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

8. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Virus Type

  • 8.1 Overview
  • 8.2 Europe Influenza Vaccines Market, By Virus Type 2022 & 2028 (%)
    • 8.2.1 Europe: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
  • 8.3 Influenza Virus Type A
    • 8.3.1 Overview
    • 8.3.2 Influenza Virus Type A : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 8.4 Influenza Virus Type B
    • 8.4.1 Overview
    • 8.4.2 Influenza Virus Type B : Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

9. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Technology

  • 9.1 Overview
  • 9.2 Europe Influenza Vaccines Market, By Technology 2022 & 2028 (%)
    • 9.2.1 Europe: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
  • 9.3 Egg-based
    • 9.3.1 Overview
    • 9.3.2 Egg-based : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 9.4 Cell-based
    • 9.4.1 Overview
    • 9.4.2 Cell-Based : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

10. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Route of Administration

  • 10.1 Overview
  • 10.2 Europe Influenza Vaccines Market, By Route of Administration 2022 & 2028 (%)
    • 10.2.1 Europe: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
    • 10.2.2 Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  • 10.3 Injection
    • 10.3.1 Overview
    • 10.3.2 Injection : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 10.4 Nasal Spray
    • 10.4.1 Overview
    • 10.4.2 Nasal Spray: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

11. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - By Target Group

  • 11.1 Overview
  • 11.2 Europe Influenza Vaccines Market, By Target Group 2022 & 2028 (%)
    • 11.2.1 Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
  • 11.3 Infants
    • 11.3.1 Overview
    • 11.3.2 Infants : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 11.4 Children
    • 11.4.1 Overview
    • 11.4.2 Children: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 11.5 Adults
    • 11.5.1 Overview
    • 11.5.2 Adults : Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)
  • 11.6 Elderly People
    • 11.6.1 Overview
    • 11.6.2 Elderly People: Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Mn)

12. Europe Influenza Vaccines Market Analysis and Forecasts To 2028 - Country Analysis

  • 12.1 Europe: Influenza Vaccines Market
    • 12.1.1 Overview
    • 12.1.2 Europe: Influenza Vaccines Market, by Country, 2022 & 2028 (%)
      • 12.1.2.1 Germany: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.1.1 Overview
        • 12.1.2.1.2 Germany: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.1.3 Germany: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.1.4 Germany: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.1.5 Germany: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.1.6 Germany: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.1.7 Germany: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
      • 12.1.2.2 UK: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.2.1 Overview
        • 12.1.2.2.2 UK: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.2.3 UK: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.2.4 UK: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.2.5 UK: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.2.6 UK: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.2.7 UK: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
      • 12.1.2.3 France: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.3.1 Overview
        • 12.1.2.3.2 France: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.3.3 France: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.3.4 France: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.3.5 France: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.3.6 France: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.3.7 France: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
      • 12.1.2.4 Italy: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.4.1 Overview
        • 12.1.2.4.2 Italy: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.4.3 Italy: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.4.4 Italy: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.4.5 Italy: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.4.6 Italy: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.4.7 Italy: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
      • 12.1.2.5 Spain: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.5.1 Overview
        • 12.1.2.5.2 Spain: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.5.3 Spain: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.5.4 Spain: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.5.5 Spain: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.5.6 Spain: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.5.7 Spain: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)
      • 12.1.2.6 Rest of Europe: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.6.1 Overview
        • 12.1.2.6.2 Rest of Europe: Influenza Vaccines Market - Revenue and Forecast to 2028 (US$ Million)
        • 12.1.2.6.3 Rest of Europe: Influenza Vaccines Market, by Vaccine Type, 2019-2028 (US$ Million)
        • 12.1.2.6.4 Rest of Europe: Influenza Vaccines Market, by Virus Type, 2019-2028 (US$ Million)
        • 12.1.2.6.5 Rest of Europe: Influenza Vaccines Market, by Technology, 2019-2028 (US$ Million)
        • 12.1.2.6.6 Rest of Europe: Influenza Vaccines Market, by Route of Administration, 2019-2028 (US$ Million)
        • 12.1.2.6.7 Rest of Europe: Influenza Vaccines Market, by Target Group, 2019-2028 (US$ Million)

13. Europe Influenza Vaccine Market -Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in the Influenza Vaccine Market, 2021-2028
  • 13.3 Inorganic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Organic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Moderna, Inc.
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 SEQIRUS
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Sanofi
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 GlaxoSmithKline plc.
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Emergent BioSolutions Inc.
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Mitsubishi Chemical Group Corporation
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Serum Institute of India Pvt. Ltd
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 MYLAN N.V.
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 AstraZeneca
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms